Clinical

The phase 3 SigVie-002 trial showed sigvotatug vedotin missed the OS end point, but the second-line subgroup showed a survival trend and manageable safety.

Joseph K. Han, MD, discusses upstream biologics, verekitug, and the future of chronic rhinosinusitis with nasal polyps treatment.

Patients with familial pulmonary fibrosis had faster FVC decline and were more likely to have a UIP pattern, supporting family history as a prognostic tool.

Patients with early relapsing multiple sclerosis (MS) were able to switch to ocrelizumab after suboptimal responses to other disease-modifying therapies.

Armored DLL3 CAR T-cell therapy from Legend Biotech/Novartis shows early responses in small cell lung cancer and neuroendocrine tumors, according to presentation at ASCO.

Hidden costs, travel, and dilation can derail DME care, but clinicians can build adherence plans that keep working adults on vision-saving therapy.

Experts warn extrapulmonary neuroendocrine carcinomas are often missed; faster pathology, rapid referrals, and early treatment improve survival.

Rare neuroendocrine carcinomas outside the lung often go missed; expert pathology and rapid referrals enable earlier treatment and better outcomes.

Anita Kumar, MD, of Memorial Sloan Kettering Cancer Center details evolving mantle cell lymphoma care: ECHO acalabrutinib-BR and chemo-free zanubrutinib BOVen triplets challenge standards.

These phase 3 studies are evaluating outcomes among patients living with polycythemia vera, myelofibrosis, and essential thrombocythemia.

Investigators described the combinations as a potential new standard of care in second-line HR+/HER2− advanced breast cancer.

Current sickle cell disease (SCD) trial eligibility criteria exclude most adults, with only 9.9% meeting inclusion thresholds, Julie Kanter, MD, says.

Zobair Younossi, MD, explains why fibrosis, not steatohepatitis resolution, best predicts MASH outcomes in trials.

Joseph K. Han, MD, discusses verekitug, unmet needs in CRSwNP, and why better biologic therapies remain necessary.

Phase 1 BALLI-01 trial results showed promising UCART22 activity in R/R B-cell ALL, with higher remission rates after a manufacturing change.

The FDA approved the first oral carbapenem, tebipenem pivoxil, for complicated UTIs, offering an alternative to intravenous therapy.

ASCO: City of Hope investigator highlights mosunetuzumab plus polatuzumab vedotin ADC/bispecific combo boosting PFS in LBCL with manageable adverse events outpatient.

This episode, titled 'What It Takes to Make the Pathway: Clinical and Operational Criteria for Adding New Combinations in RRFL,' features Ryan Haumschild, PharmD, MS, MBA, CPEL discussing the following critical question:

In 'From Data to Practice: Interpreting inMIND Trial Results and the Role of Tafasitamab in RRFL,' Ryan Haumschild, PharmD, MS, MBA, CPEL delves into the following critical questions

Richard Bogan, MD, discusses trial data coming out of the VIBRANCE studies for patients with narcolepsy type 2 and idiopathic hypersomnia.

Nipocalimab showed rapid responses within 1 week in warm autoimmune hemolytic anemia (wAIHA), as well as a favorable safety profile.

Tarik Asselah, MD, PhD, explains why HDV RNA suppression deepened through 2 years with tobevibart plus elebsiran.

This new analysis offers some of the most rigorous real-world data to guide treatment decisions for TP53 wild-type chronic lymphocytic leukemia.

Pooled TETON trial data showed inhaled treprostinil preserved lung function in IPF, supporting an FDA submission planned for 2026.